65,437 trials
Gout
Primary: Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 1. — 80.8; 87.0; 46.0 percentage of subjects
Leukemia
Primary: Number of Patients With Natural Killer (NK) Cell Expansion — 2 Participants
Graft vs Host Disease · Kidney Transplantation
Primary: Mean Creatinine Clearance Rate — 56.800; 53.449 ml/min — p=0.6081
Anemia
Primary: Mean Change From Baseline to the Highest Hemoglobin up to Day 71 — 1.3; .7 g/dL
Chronic Hepatitis c · Cirrhosis, Liver · Fibrosis, Liver
Primary: Progression of Liver Disease as Indicated by Death, Hepatic Decompensation, Hepatocellular Carcinoma, or for Patients With Noncirrhotic Fibrosis at Baseline, an Increase…
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Body Weight — -6.16; -3.97 kg — p=0.0030
Obesity
Primary: Change in Body Weight — 109.48; 107.64; -5.06; -1.61 kg — p=<0.0001
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 26 for the Per Protocol (PP) Population — -2.01; -1.75 percent — p=<0.0001
Osteoarthritis, Hip · Osteoarthritis, Knee · Lower Back Pain
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAE) — 766; 202 Participants
Allergic Rhinitis · Chronic Urticaria
Primary: Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in Ventricular Rate (VR) — -1.5; 1.3 beats per minute
Mucopolysaccharidosis I · Mucopolysaccharidosis VI · Mannosidosis
Primary: Mean Percentage of Donor Cells in Study Population (Chimerism). — 85.8; 73.2; 84.6; 81.1 Percentage
Hypercholesterolemia
Primary: Log[Area-under-the-plasma-concentration-curve(AUC) 0-8 Hours 7-ketocholesterol] After an Oral Bolus — 1.925; 2.177 Log(mg*hr/dl) — p=0.03
Restless Legs Syndrome
Primary: Average Numeric Symptom Severity Score After Single Dose of Rotigotine Nasal Spray or Matching Placebo — 2.6; 2.2; 2.5; 2.0 score on a scale
Gastrointestinal Stromal Tumors
Primary: Number of Participants With Clinical Benefit Response (CBR) According to RECIST — 15; 17; 32 participants
Myelodysplastic Syndrome
Primary: Number of Participants Who Achieved Overall Response — 33 participants